MA33378B1 - Nouveaux sels de fumarate d'un antagoniste des récepteurs h3 de l'histamine - Google Patents

Nouveaux sels de fumarate d'un antagoniste des récepteurs h3 de l'histamine

Info

Publication number
MA33378B1
MA33378B1 MA34475A MA34475A MA33378B1 MA 33378 B1 MA33378 B1 MA 33378B1 MA 34475 A MA34475 A MA 34475A MA 34475 A MA34475 A MA 34475A MA 33378 B1 MA33378 B1 MA 33378B1
Authority
MA
Morocco
Prior art keywords
histamine
new
receptor antagonist
fumarate salts
fumarate
Prior art date
Application number
MA34475A
Other languages
Arabic (ar)
English (en)
Inventor
Beverly C Langevin
Robert Allan Farr
Dinubhai H Shah
Daniel Sherer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33378B1 publication Critical patent/MA33378B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur des sels fumarates de 2-(cyclohexylméthyl)-N-{2-[(2S)-1-méthylpyrrolidin-2-yl]éthyl}-1,2,3,4-tétrahydroisoquinoléine-7-sulfonamide, sur des compositions pharmaceutiques les contenant, sur des procédés permettant de les fabriquer et sur des procédés d'utilisation de ceux-ci.
MA34475A 2009-06-26 2010-06-24 Nouveaux sels de fumarate d'un antagoniste des récepteurs h3 de l'histamine MA33378B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22068309P 2009-06-26 2009-06-26
FR0959110 2009-12-17
PCT/US2010/039731 WO2010151611A1 (fr) 2009-06-26 2010-06-24 Nouveaux sels fumarates d'un antagoniste des récepteurs h3 de l'histamine

Publications (1)

Publication Number Publication Date
MA33378B1 true MA33378B1 (fr) 2012-06-01

Family

ID=43386878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34475A MA33378B1 (fr) 2009-06-26 2010-06-24 Nouveaux sels de fumarate d'un antagoniste des récepteurs h3 de l'histamine

Country Status (25)

Country Link
US (1) US8664245B2 (fr)
EP (1) EP2445899B1 (fr)
JP (1) JP6053519B2 (fr)
KR (1) KR101804749B1 (fr)
CN (1) CN102803247B (fr)
AR (1) AR077223A1 (fr)
AU (1) AU2010264422B2 (fr)
BR (1) BRPI1011258A2 (fr)
CA (1) CA2766154C (fr)
CO (1) CO6480943A2 (fr)
DO (1) DOP2011000398A (fr)
ES (1) ES2587064T3 (fr)
IL (1) IL216924A0 (fr)
MA (1) MA33378B1 (fr)
MX (1) MX2011012824A (fr)
NZ (1) NZ597219A (fr)
PE (1) PE20121403A1 (fr)
PL (1) PL2445899T3 (fr)
RU (1) RU2537847C2 (fr)
SG (1) SG176645A1 (fr)
TN (1) TN2011000620A1 (fr)
TW (1) TWI462915B (fr)
UY (1) UY32738A (fr)
WO (1) WO2010151611A1 (fr)
ZA (1) ZA201108838B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
WO2013151982A1 (fr) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés
EP2647377A1 (fr) * 2012-04-06 2013-10-09 Sanofi Utilisation d'un antagoniste du récepteur h3 pour le traitement de la maladie d'Alzheimer
JP2015524400A (ja) * 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製
EP3043799A1 (fr) * 2013-09-09 2016-07-20 Sanofi Antagoniste des récepteurs h3 combiné à un inhibiteur de la cholinestérase et utilisé dans le cadre du traitement de la maladie d'alzheimer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228170A (en) 1979-08-30 1980-10-14 Smithkline Corporation 7- and/or 8-Sulfur substituted 1,2,3,4-tetrahydroisoquinoline compounds
EP0306375A1 (fr) 1987-08-07 1989-03-08 Synthelabo Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique
IL89156A (en) 1988-07-12 1993-05-13 Synthelabo Derivatives of 2-((4-piperidinyl) methyl)- 1,2,3,4- tetrahydroisoquinoline, their preparation and their application in therapeutics
EP1200410A1 (fr) 1999-07-29 2002-05-02 Egis Gyogyszergyar Rt. Derives d'isoquinoline, compositions pharmaceutiques contenant ces derives et procede de preparation du principe actif
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
WO2003055848A2 (fr) 2001-12-26 2003-07-10 Bayer Healthcare Ag Derives d'uree
US7790231B2 (en) 2003-07-10 2010-09-07 Brewer Science Inc. Automated process and apparatus for planarization of topographical surfaces
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
CA2602336A1 (fr) * 2005-03-31 2006-10-05 Ucb Pharma S.A. Composes comprenant un groupe fonctionnel d'oxazole ou de thiazole, processus de fabrication et leur utilisation
WO2007108936A2 (fr) * 2006-03-15 2007-09-27 Wyeth Azacyclylamines avec substitution n en tant qu'antagonistes de l'histamine-3
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
WO2008144305A1 (fr) * 2007-05-18 2008-11-27 Janssen Pharmaceutica N.V. Tétrahydroisoquinolines diaryl-substituées utilisables en tant que modulateurs du récepteur h3 de l'histamine et du transporteur de la sérotonine
CA2693138A1 (fr) * 2007-07-16 2009-01-22 Wyeth Llc Derives d'aminoalkylazole en tant qu'antagonistes d'histamine-3

Also Published As

Publication number Publication date
JP6053519B2 (ja) 2016-12-27
TN2011000620A1 (en) 2013-05-24
CA2766154A1 (fr) 2010-12-29
US20120149728A1 (en) 2012-06-14
WO2010151611A1 (fr) 2010-12-29
KR20120039555A (ko) 2012-04-25
US8664245B2 (en) 2014-03-04
CN102803247A (zh) 2012-11-28
JP2012531424A (ja) 2012-12-10
AU2010264422A1 (en) 2012-02-02
NZ597219A (en) 2013-05-31
AU2010264422B2 (en) 2014-12-18
AR077223A1 (es) 2011-08-10
RU2012102671A (ru) 2013-08-10
SG176645A1 (en) 2012-01-30
DOP2011000398A (es) 2012-01-31
CN102803247B (zh) 2014-11-05
CA2766154C (fr) 2015-04-07
TWI462915B (zh) 2014-12-01
PL2445899T3 (pl) 2017-08-31
EP2445899B1 (fr) 2016-05-11
KR101804749B1 (ko) 2017-12-05
MX2011012824A (es) 2012-01-27
UY32738A (es) 2011-01-31
ES2587064T3 (es) 2016-10-20
TW201103911A (en) 2011-02-01
EP2445899A1 (fr) 2012-05-02
RU2537847C2 (ru) 2015-01-10
IL216924A0 (en) 2012-03-01
BRPI1011258A2 (pt) 2016-03-22
PE20121403A1 (es) 2012-11-02
CO6480943A2 (es) 2012-07-16
ZA201108838B (en) 2012-08-29

Similar Documents

Publication Publication Date Title
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
EP2318028A4 (fr) Antagonistes d activine-actriia et utilisations pour augmenter les taux d' érythrocytes
EP2087128A4 (fr) Composition et procédés pour des antigènes immunodominants
EP2350024A4 (fr) Procédé amélioré de synthèse d'antagonistes de récepteur de l'endothéline
EP2320904A4 (fr) Inhibiteurs aminopyrimidine des récepteurs de l'histamine destinés au traitement d'une maladie
EP2324029A4 (fr) Inhibiteurs hétérocyliques des récepteurs de l'histamine destinés au traitement d'une maladie
EP2545058A4 (fr) Inhibiteurs hétérocycliques de récepteurs de l'histamine destinés au traitement de maladie
EP2348846A4 (fr) Antagonistes des récepteurs de l'orexine de type azépane disubstitué
UA105794C2 (uk) 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
EP2499486A4 (fr) Compositions, kits, et procédés pour l'identification, l'évaluation, la prévention, et la thérapie d'un cancer
EP2276469A4 (fr) Agonistes des récepteurs alpha-adrénergiques destinés au traitement de la discopathie dégénérative
EP2321426A4 (fr) Compositions pour la détection de la mort cellulaire et procédés d 'utilisation associés
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
EP2134171A4 (fr) Compositions et procédés pour la formation et le remodelage osseux
EP2424554A4 (fr) Nouveaux inhibiteurs de la sphingosine kinase de type 1, compositions et procédés pour l'utiliser
AR079198A1 (es) Sales de 4-(2-((5-metil-1-(2-naftalenil) -1h pirazol -3- il)oxi) etil) morfolina
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
EA201600436A1 (ru) Кристаллическая солевая форма (s)-(2-(6-хлор-7-метил-1h-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора
EP2293670A4 (fr) Compositions et procédés pour traitement de mycose d'ongle
EA201270261A1 (ru) Соли леналидомида
EP2271346A4 (fr) Antagonistes des récepteurs cgrp monocycliques
TN2011000620A1 (en) Novel fumarate salts of a histamine h3 receptor antagonist
EP2336352A4 (fr) Biocapteur pour la détection d'anticorps anti-vih
EP2226632A4 (fr) Procédé pour le criblage d'un agent protégeant les cellules
MA34144B1 (fr) Procédé de préparation du 2-(cyclohexylméthyl)-n-{2-[(2s)-1-méthylpyrrolidin-2-yl]éthyl}-1,2,3,4- tétrahydroisoquinoléine-7-sulfonamide